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Hyperfunctioning thyroid 
cancer: a five-year follow-up
Carcinoma de tireoide hiperfuncionante: seguimento de cinco anos 
Monalisa Ferreira Azevedo1, Luiz Augusto Casulari1 
Summary
Differentiated thyroid cancer rarely occurs in association with hyperfunctioning nodules. We 
describe a case of a 47-year-old woman who developed symptoms of hyperthyroidism associa-
ted with a palpable thyroid nodule. Thyroid scintigraphy showed an autonomous nodule, and 
fine-needle aspiration biopsy was suggestive of papillary carcinoma. Laboratorial findings were 
consistent with the diagnosis of hyperthyroidism. The patient underwent thyroidectomy and a 
papillary carcinoma of 3.0 x 3.0 x 2.0 cm, follicular variant, was described by histological exami-
nation. The surrounding thyroid tissue was normal. Postoperatively, the patient received 100 mCi 
of 131I, and whole body scans detected only residual uptake. No evidence of metastasis was detec-
ted during five years of follow-up. Hot thyroid nodules rarely harbor malignancies, and this case 
illustrated that, when a carcinoma occurs the prognosis seems to be very good with no evidence 
of metastatic dissemination during a long-term follow-up. Arq Bras Endocrinol Metab. 2010;54(1):78-80
Sumário
O câncer diferenciado de tireoide raramente ocorre em associação a nódulos hiperfuncionan-
tes. Foi descrito aqui o caso de uma paciente de 47 anos de idade que desenvolveu sintomas 
de hipertireoidismo associados a um nódulo tireoidiano palpável. A cintilografia da tireoide 
mostrou tratar-se de um nódulo autônomo, e a biópsia por punção aspirativa por agulha fina foi 
sugestiva de carcinoma papilar. Os achados laboratoriais foram consistentes com o diagnóstico 
de hipertireoidismo. A paciente foi submetida à tireoidectomia e um carcinoma papilar de 3,0 x 
3,0 x 2,0 cm, variante folicular, foi descrito por exame histopatológico. O tecido tireoidiano cir-
cunjacente era normal. No pós-operatório a paciente recebeu 100 mCi de 131I, e a cintilografia de 
corpo inteiro mostrou apenas captação residual. Nenhuma metástase foi identificada ao longo 
de cinco anos de acompanhamento. Nódulos quentes raramente albergam doença maligna, 
e este caso demonstrou que, quando ocorre carcinoma, o prognóstico parece ser muito bom, 
sem evidência de disseminação metastática em longo prazo. Arq Bras Endocrinol Metab. 2010;54(1):78-80
Thyroid cancer clinically hyperfunctioning and lea-ding to hyperthyroidism represents a very rare con-
dition. Less than 1% of the autonomous thyroid nodules 
actually harbor a malignant neoplasm (1). In the majo-
rity of cases the carcinoma coexists with a hyperfunc-
tioning adenomatous tissue not being responsible for 
the toxic state of the gland (2). Until 1998, only about 
20 cases of toxic thyroid carcinoma were reported in 
the literature, and there was a higher prevalence of the 
papillary type of cancer among these patients (1,3). In 
2002, Als and cols. (4) described a series of 19 patients 
with malignant hyperfunctioning nodules in Switzer-
land and the higher prevalence was of the follicular type 
of cancer. A few similar cases have been described recen-
tly (5,6) and the pathogenesis of this clinical condition 
is still unknown.
We described the case of a 47-year-old woman who had 
a papillary thyroid carcinoma of 3.0 cm of diameter, which 
was functionally autonomous and scintigraphically hot.
CaSe report
A 47-year-old woman was referred to us in May 2003, 
because of a thyroid nodule and hyperthyroidism. She 
complained of weight loss (not quantified), nervous-
ness, tremor, fatigue and insomnia, which had begun 
three months earlier. Also, she had been noting a slow 
and progressive increase in the anterior neck region dur-
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there was a positive family history for non-neoplastic 
thyroid disease. There was no history of previous radia-
tion on her cervical region. On physical examination, 
she weighed 54 kg and was 160 cm tall (body mass in-
dex, BMI, 21.09). Her resting pulse rate was 94 beats/
min, and her blood pressure was 140 x 90 mmHg. On 
thyroid topography, an approximately 2.5 cm, mobile, 
painless nodule was palpable on the right side. No lymph 
nodes were detectable on examination of the neck.
Ultrasonographic study showed a solid nodule of 2.6 
cm diameter in the right thyroid lobe, with the rest of 
the gland echographically normal. Scintigraphy with 131I 
showed the presence of an area of high iodine uptake 
occupying the right lobe of the thyroid, corresponding 
to a hyperfunctioning nodule, and no uptake was de-
tected in the remaining bed (Figure 1A). Radioiodine 
uptake of the neck region was 32% after 24 hours (nor-
mal range, 10%-45%). Free T4 serum levels were 2.75 
ng/dL (normal range, 0.7-1.5 ng/dL), total T3 was 
3.53 ng/mL (normal range, 0.7-2.2 ng/mL) and TSH 
was less than 0.05 mUI/mL (normal range, 0.3-5.0 
mUI/mL). On the basis of these findings, a diagnosis of 
an autonomously functioning thyroid nodule was made. 
The patient was also submitted to a fine-needle as-
piration biopsy of the nodule that was suggestive of a 
papillary carcinoma (Figure 1B). Methimazole therapy 
was initiated (40 mg/day) and after two months the 
patient was in euthyroidism. In August 2003, total 
thyroidectomy was performed and the postoperative 
course presented no complications.
Histological examination confirmed that the nod-
ule, measuring 3.0 x 3.0 x 2.0 cm was a papillary carci-
noma, follicular variant, with capsular and vascular inva-
sion (Figure 1C). The tumor was not multicentric, and 
the rest of the thyroid gland was histologically normal.
Two months after surgery the patient was in frank 
hypothyroidism and a 100 mCi 131I dose was adminis-
tered. 131I whole-body scan showed only some uptake 
in the cervical area. Subsequently, levothyroxine was 
instituted in a dose of 150 mg per day to suppress the 
TSH production by the pituitary gland. One year after 
surgery a 131I whole-body scan was performed and again 
only residual uptake in the cervical area was observed. 
Thyroglobulin levels measured on hypothyroidism, 
were undetectable and antithyroglobulin antibodies 
were negative. The patient was maintained on levothy-
roxine suppressive therapy and three years after surgery 
cervical ultrasonography showed a heterogeneous oval 
nodule with internal calcifications, measuring 7 x 12 
mm, localized on thyroid topography. Fine needle as-
piration biopsy was negative for malignancy and thyro-
globulin measured in the aspirate washout was 0.2 ng/
dL. At that time, thyroglobulin serum levels were 0.4 
ng/mL, serum antibodies were negative and no inter-
vention was performed. The dose of levothyroxine was 
reduced to 125 mg/day and no evidence of recurrence 
of the disease was observed during the next two years 
of follow-up, once thyroglobulin and antithyroglobulin 
antibodies were undetectable in the patient serum. 
DiSCuSSion
The hyperfunctioning thyroid nodule has been gener-
ally considered a benign disease requiring a conserva-
tive therapeutic approach and in the past it was believed 
that hyperthyroidism excluded the possibility of a thy-
roid carcinoma. However, in the last years, there has 
been citation of cases of thyroid cancer associated with 
solitary toxic goiter, multinodular toxic goiter, diffuse 
toxic goiter (Graves’ disease) and hyperfunctioning 
thyroid metastases (3,7-12).
We described here the case of a hyperthyroid woman 
who had a diagnostic suspicion of thyroid carcinoma in 
a fine-needle aspiration biopsy which is a very uncom-
mon feature. The literature reports a crescent number 
of cases of hyperthyroidism associated with thyroid 
microcarcinomas diagnosticated after histopathologi-
cal examination, while malignant tumors of more than 
1.5 cm diameter, which are proved to be autonomous, 
are very rare. The most frequent histological type of 
cancer in these cases seems to be the papillary (70% 
to 75%), followed by the follicular type (20% to 25%). 
Medullary and anaplastic forms are rarely observed (7). 
Figure 1. (A) Thyroid 131I-Scintigraphy shows a hyperfunctioning nodule in 
the right lobe; (B) aspirate smears show follicular clusters of cells with 
large and pale nuclei, and rare intranuclear inclusions; (C) histologic 
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In a five-year follow-up, our patient presented no 
evidence of metastases. The age at diagnosis, sex, histo-
pathologic type (a papillary carcinoma), and low diam-
eter of the tumor (less than 4 cm) were probably dis-
tinguished characteristics that contributed to the good 
outcome in this period. In the previous analysis of 19 
patients followed-up for a median duration of 6 years, 
frequency of locoregional and distant metastases did not 
differ from differentiated thyroid carcinomas in general 
(4). The survival prognosis was close to that of matched 
follicular subtypes of differentiated thyroid cancer (4). 
In the same study, 4 out of 19 patients harbored a pap-
illary carcinoma and 2 of them were follicular variants. 
The first was a 56-year-old man who presented a car-
cinoma T2N0M0 at the initial stage with no evidence 
of distant metastases during 17 years of follow-up. The 
second patient was also a man, who had the diagno-
sis at the age of 74 and the tumor was a T4N0M0. 
He presented distant metastases during follow-up, and 
after six years he was still alive (4). The etiopathogen-
esis of coexisting hyperthyroidism and carcinoma is still 
unknown. Concerning autonomous thyroid adenomas, 
mutations in the TSH receptor gene (TSHR) and in the 
Gsa protein gene (GNAS1) have been identified to be 
the cause of the majority of the cases (13,14). Also, in 
hyperfunctioning carcinomas mutations in the TSH re-
ceptor gene have been described (6,15-17). However, 
from the data available in the literature, it seems that 
activation of the cAMP pathway is not a major player 
in cell transformation. Most hyperfunctioning tumors 
harbor both TSHR mutations and proto-oncogene 
mutations. This coexistence suggests that carcinomas 
arise from the activity of classical oncogenes such as 
RAS and RET/PTC, and that the TSHR and GNAS1 
mutations confer hyperfunctioning features to the neo-
plasms (18). In the present study, we did not investigate 
the possibility of mutations that could be related to the 
pathogenesis of the disease.
Considering the rarity of the association of thyroid 
cancer and hyperthyroidism, at present, the evidences 
available are not enough to recommend the systematic 
evaluation of oncological risk in all hot thyroid nodes, 
which may be cumbersome and not necessarily cost-effec-
tive. Further studies would be helpful to clarify this issue.
In conclusion, the present report illustrates that hy-
perthyroidism does not exclude thyroid malignancy and 
confirms other published cases in which the prognosis of 
the carcinoma seems to be very good, with elevated sur-
vival rates, especially in the papillary histological subtype. 
Disclosure: no potential conflict of interest relevant to this article 
was reported. 
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